A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease
A meta-analysis
Jie He, BA, Jiang-Tao Lin, MM∗

Abstract
Background: Combinations of long-acting bronchodilators with different mechanisms of action are recommended to improve lung function, health status, and reduce risk of adverse events of chronic obstructive pulmonary disease (COPD). It is unclear whether the new combination therapy with long-acting muscarinic antagonist (LAMA) tiotropium (TIO) and long acting beta-agonists (LABA) olodaterol (OLO) was superior to tiotropium alone.

Methods: We measured the efficacy of the TIO/OLO combination vs TIO alone for COPD patients based on electronic databases up to February 2019. After rigorous quality review, data was extracted from eligible trials. All the main outcomes were pooled analysis using RevMan software.

Results: A total of 6 randomized controlled trials (RCTs) were identified. The pooled results of our meta-analysis demonstrated that FEV1 [MD = 0.03, 95% CI (–0.01, 0.07), P = .18], FVC [MD = –0.06, 0.00, P = .09] and FEV1%pred [MD = 0.35, 95%CI (–0.30, 0.99), P = .35] all showed no significant difference between the 2 groups. The overall incidence of adverse effects [AEs] [OR = 1.04, 95% CI (0.82, 1.32), P = .72] in the combination group was similar to that of the TIO alone group, without statistical significance.

Conclusion: These studies reported that the TIO/OLO combination did not show superior effects than tiotropium alone for COPD. Additionally, both therapies were well tolerated.

Abbreviations: AEs = adverse effects, COPD = chronic obstructive pulmonary disease, LABA = long acting beta-agonists, LAMA = long-acting muscarinic antagonist, OLO = olodaterol, RCTs = randomized controlled trials, ROBI = the risk of bias items, TIO = tiotropium.

Keywords: COPD, meta-analysis, olodaterol, tiotropium, tiotropium/olodaterol combination

1. Introduction
Long-acting bronchodilators represent the backbone of an effective maintenance therapy for chronic obstructive pulmonary disease (COPD). Tiotropium was the first once-daily long-acting muscarinic antagonist (LAMA) to be used to treat COPD and can improve lung function, health status, and reduces risk of exacerbations. Furthermore, the combination of a LAMA and a long-acting β2-agonist (LABA) has been recommended to patients who remain symptomatic on a single long-acting agent.

The LABA olodaterol has a different mechanism of action from tiotropium while exhibiting symptomatic benefits and preferable exercise capacity and has been accepted as a complementary bronchodilator to tiotropium in patients with COPD. The rationale for the combination therapy with different modes of action is to demonstrate improvements of bronchodilation for equivalent or lesser adverse effects than a single bronchodilator.

To date, limited trials have been conducted on whether combining olodaterol with tiotropium offers additional benefits over tiotropium alone in preventing exacerbations. Given that previous studies have reported controversial and sometimes conflicting results because of their toxicity or limited efficacy, it remains unclear how well the TIO/OLO combination performs against tiotropium alone. The objective of this meta-analysis was to investigate the efficacy and toxicity of TIO/OLO comparing with TIO alone as a treatment option for COPD.

2. Methods and materials
2.1. Retrieval strategy
We retrieved published articles on the efficacy and safety of TIO/OLO comparing with TIO alone as a treatment option for COPD
up to February, 2019. The searchable databases included PubMed, EMBASE, and the Cochrane Library. The following keywords were used: “chronic obstructive pulmonary disease” AND “Tiotropium” AND “Olodaterol” AND “Tiotropium/ olodaterol combination”. There was no language restriction. We also searched the references of eligible studies and reviewed studies from all of the relevant publications to identify any additional relevant studies. Since animal experiment or human was not involved in this study, the ethical approval was not necessary.

2.2. Inclusion criteria

Articles that were related to the following inclusion criteria were included in this analysis:
1. The studies were designed as randomized controlled trials (RCTs);
2. Trials focused on the TIO/OLO combination vs tiotropium alone;
3. The 2 groups provided complete data of treated patients with COPD;
4. The results of interest were efficacy and adverse effects;
5. Only studies with full texts were included.

2.3. Quality evaluation

Quality evaluation was carried out by 2 investigators. The risk of bias items (ROBI) recommended by The Cochrane Handbook for Systematic Reviews of Interventions was used.

2.4. Data extraction

Two authors separately extracted the relevant data from individual studies, and differences were settled through discussion. A self-designed data was based on the following parameters from the eligible studies: names of authors, publication year, sample size, mean age, and outcomes of interest. We extracted the corresponding variables and adjusted risk estimates of mortality with 95%CIs.

2.5. Statistical analysis

Review Manager version 5.3 software (Revman; The Cochrane Collaboration Oxford, United Kingdom) was used for statistical analysis. A sensitivity analysis was also performed to examine the impact on the overall results, depending on the degree of heterogeneity across the included studies. To assess the heterogeneity of trials and determine the model for analysis, \( I^2 \) statistic and Chi-Squared tests were conducted.[9] The fixed-effects model was used if the assessment of heterogeneity was insignificant (\( I^2 \leq 50\% \)). If the source of heterogeneity was not insignificant (\( I^2 > 50\% \)), we used the random-effects model for further analysis.[9] A \( P \) value less than .05 was identified as statistically significant difference. Forest plots indicated the results of our meta-analysis.

3. Results

3.1. Overview of literature search and study characteristics

Totally, 102 articles were identified initially. Based on the criteria described in the methods, 96 articles were excluded due to lack of results. Finally, a total of 6 RCTs\[^{6,10-14}\] including 8 trials were assessed for eligibility in the meta-analysis (Fig. 1). Table 1 has a brief description of these 8 trials.

3.2. Clinical and methodological heterogeneity

3.2.1. Pooled analysis of FEV1 comparing the TIO/OLO combination vs TIO alone. Pooling the FEV1 from studies demonstrated that no benefit was found between the TIO/OLO combination and TIO alone [MD = 0.03, 95% CI (–0.01, 0.07), \( P = .18 \)], and the data are shown in Figure 2.

3.2.2. Pooled analysis of FVC comparing the TIO/OLO combination vs TIO alone. Three trials reported FVC data. As displayed in Figure 3, the pooled estimates of effect sizes showed no significant statistical difference in FVC between the 2 groups [MD = -0.03, 95% CI (-0.06, 0.00), \( P = .09 \)].

3.2.3. Pooled analysis of FEV1%pred comparing the TIO/OLO combination vs TIO alone. Systematic evaluations of FEV1%pred are shown in the Figure 4. The pooled results showed no remarkable difference between the 2 groups [MD = 0.35, 95% CI (-0.30, 0.99), \( P = .29 \)].

3.2.4. Pooled analysis of AEs comparing the TIO/OLO combination vs TIO alone. In terms of safety, the overall incidence of AEs [OR = 1.01, 95% CI (0.93, 1.09), \( P = .87 \)] (Fig. 5) and serious AEs [OR = 1.04, 95% CI (0.82, 1.32), \( P = .72 \)] (Fig. 6) in the combination group were similar to the TIO alone group, and did not reach a statistically significant level.

Table 1

The primary characteristics of the eligible studies in more detail.

| Studies year | NCT          | FEV1          | Patients number | Median age |
|--------------|--------------|---------------|-----------------|------------|
|              | Tiotropium+olodaterol | Tiotropium   | Tiotropium+olodaterol | Tiotropium |
| Singh D (1) (2015) | NCT01964352  | 203           | 203              | 64.7       | 64.9       |
| Singh D (2) (2015) | NCT02006732  | 202           | 203              | 65.2       | 64.7       |
| Beeh KM (2015)   | NCT01559116  | 219           | 219              | 61.1       | 61.1       |
| Zuwallack R (2) (2014) | NCT01696058  | 566           | 569              | 64.6       | 63.6       |
| Zuwallack R (1) (2014) | NCT01694771  | 567           | 565              | 64.3       | 64.8       |
| Buhl R (2015)    | NCT01431274  | 1030          | 1033             | 64.1       | 63.9       |
| Ichino M (2016)  | NCT01431274 + NCT01431287  | 78            | 72               | 69.1       | 69.1       |
| Calverley P (2018) | NCT02206138  | 2030          | 2041             | 66.5       | 66.3       |
4. Discussion

Long-acting bronchodilators have been recommended as the cornerstone therapy of COPD. Recently, combining drugs with different mechanisms of action has been prescribed in clinical trial, such as LAMA+LABA.[15,16] Olopatadine is a novel once-daily LABA that has been reported as a combination partner for tiotropium, with additional improvements in lung function matching pharmacokinetic and pharmacodynamic profiles.[17] Previous studies have shown that olopatadine may improve efficacy than with tiotropium alone for COPD.[18,19] However, there has also been much debate about the clinical benefit of combination treatments in COPD, as greater lung-function benefits with these combinations have often been associated with only small benefit or did not translate to a greater benefit on patient-reported results compared to mono-therapies.[16]

In our analysis, we fail to reach our expected significance level with the combination group. Several potential reasons may explain this. Specific subgroups of cases might have been more responsive to combination therapy, especially those who have already been treated with ICS. Patients who have taken corticosteroids are associated with a higher risk of exacerbation[14] and could benefit from additional therapy.

To date, no trials have reported any differences between ethnic groups in systemic exposure to inhaled medications.[20,21] Meanwhile, there were key differences between Japanese populations and the overall cases.

Previous studies have shown that Japanese COPD patients may experience fewer exacerbations than Caucasian patients.[22] Because of the differences in patient populations, the measurement of airflow improvements is difficult to undertake.

In addition, several studies have reported that women reached a higher risk of exacerbation[23,24] although the causes are not well understood. Alternatively, bronchodilators might have a ceiling effect in reducing exacerbations. Studies have indicated that combining LABAs and LAMAs produces less improvement than individual drugs.[25]

Meanwhile, the incidence of AEs was similar between 2 treatments, with no increase in incidence with the TIO/OLO combination compared to tiotropium alone. These findings are consistent with the safety analysis of many previous studies, which found that both 2 groups have a similar number of patients with AEs.[12,14]

5. Limitations

Our analysis is based on the well-maintained and updated databases. Nevertheless, potential bias exists by intrinsically different study designs, and clinical heterogeneities among studies should be taken into consideration in the interpretation of our results. Moreover, as this study was a study-level meta-analysis, due to lack of patient-level data, imbalances among the included...
Retraction studies might affect the results, even though all the included studies are RCTs. Future research should aim to identify subgroups of patients who are more likely to achieve benefit from the combination group.

6. Conclusions
Overall, we did not find additional benefits of tiotropium + olodaterol compared with tiotropium mono-therapy in COPD. However, our data do not negate the symptomatic benefits with...
this dual bronchodilator combination, but emphasize the need to identify those patients who could benefit from additional bronchodilator therapy.

**Author contributions**

JH and JTL have made substantial contributions to conception and design of the study, written the manuscript; JH searched literature, extracted data from the collected literature and analyzed the data; JTL revised the manuscript; All authors approved the final version of the manuscript.

**References**

[1] Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med 2017;195:537.

[2] O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40.

[3] Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD: Chest 2005;128:1168-78. Respir Med Copd 2006;1: 146-146.

[4] Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014;2014:697-714.

[5] Maltais F, Kirsten AM, Hamilton A, et al. Evaluation of the effects of olodaterol on exercise endurance in patients with COPD: results from two 6-week studies. Chest 2013;144:748A–1748A.

[6] Singh D, Ferguson GT, Boltschek J, et al. Tiotropium olodaterol shows clinically meaningful improvements in quality of life. Respir Med 2015;109:1312-9.

[7] Beeh KM, Derom E, Cheflesmes J, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat® (ENERGITO® study). Int J Chron Obstruct Pulmon Dis 2016;11:193.

[8] Group APCR. Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective. Respiratory 2010;10:9-17.

[9] Higgins JP, Thompson SG. Quantifying heterogeneity in meta-analysis. Stat Med 2002;21:1539.

[10] Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulmon Pharmacol Therap 2015;32:53-9.

[11] Zuwailack R, Allen L, Hernandez G, et al. Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studies.[J]. Int J Chron Obstruct Pulmon Dis 2014;9:1133–44.

[12] Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)[J]. Eur Respir J 2015;45:969–79.

[13] Masakazu I, Hirotsuki T, Ayako T, et al. The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado. Int J Chron Obstruct Pulmon Dis 2016;11:2017–27.

[14] Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial[J]. Lancet Resp Med 2018;52213260013801024.

[15] Bates D, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484–94.

[16] Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umecrichtine plus vilanterol versus tiotropium, vilanterol, or umecrichtine monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multi-centre, blinded, randomised controlled trials. Lancet Resp Med 2014;2:472–86.

[17] Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled 2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmocol Exp Ther 2010;334:53–62.

[18] Maltais F, Becker D, Webster D, et al. Four weeks once daily treatment with tiotropium/olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients. Eur Respir J 2010;36(Suppl. 54):1014s.

[19] Allers B, Maleki-Yazdi MR, Hamilton A, et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD. Eur Respir J 2012;40(Suppl. 56):235s–66.

[20] Ichinohe T, Takehara A, Inamoto T, et al. Efficacy and safety of the long-acting 2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015;10:1673–83.

[21] Hosoe M, Woessner R, Matsuhashi S, et al. Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease, Clin Drug Investig 2011;31:247.

[22] Suzuki M, Makita H, Ito YM, et al. Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study. Eur Respir J 2013;43:1289–97.

[23] Japanese Respiratory Society.COPD Guidelines for Diagnosis and Treatment. 4th ed.Tokyo: Japanese Respiratory Society; 2013.

[24] Masakazu I, Masaharu N, Manabu A, et al. Tiotropium/olodaterol fixed-dose combination versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study. Int J Chron Obstruct Pulmon Dis 2018;13:2147–56.

[25] Calverley P, Vliss B. New Pharmacotherapeutic approaches for chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2015; 36:523–42.